TLDRFirefly Neuroscience AIFF stock surged 35% after NeuroSigma partnership announcement.Partnership expands Monarch ADHD therapy access through Firefly clinician network.Monarch eTNS System offers FDA-cleared non-drug ADHD treatment for children.Firefly Evoke platform analyzes brain activity using EEG and ERP technology.Collaboration targets improved personalized ADHD care through advanced solutions.Firefly Neuroscience Inc. (AIFF) stock climbed 34.87% to $1.6050 after announcing a strategic partnership with NeuroSigma. The agreement expands access to NeuroSigma’s Monarch eTNS System through Firefly’s nationwide clinician network. The collaboration combines brain assessment technology and a non-drug ADHD treatment option for eligible children.Firefly Neuroscience, Inc., AIFFFirefly Expands Clinician Network Through NeuroSigma PartnershipFirefly will introduce the Monarch eTNS System to clinicians using its Evoke platform. The partnership targets psychiatry, neurology, and behavioral health practices across the United States. Meanwhile, NeuroSigma will provide training, prescribing support, and product fulfillment services.The Monarch eTNS System received clearance from the U.S. Food and Drug Administration for pediatric ADHD treatment. The device offers a non-medication approach for children between seven and twelve years old. It delivers mild external trigeminal nerve stimulation through a forehead patch during sleep.Firefly’s Evoke platform uses quantitative EEG and ERP testing with advanced analytics. The system analyzes brain activity through a database containing more than 200,000 EEG and ERP scans. Therefore, clinicians can access objective information about brain function and track patient changes over time.AIFF Stock Gains Momentum Following Healthcare Technology ExpansionThe partnership follows Firefly’s continued development of neuroscience solutions focused on personalized care. In March 2026, the company announced EEG and ERP biomarker discoveries linked to ADHD presentations. The findings may support future research into treatment selection and patient monitoring.NeuroSigma expanded availability of its second-generation Monarch device in July 2026. The company also introduced additional payment options in September to support family access. The expansion followed a waitlist exceeding 1,500 patients, caregivers, and healthcare providers.Firefly Neuroscience develops technology that supports clinicians in understanding brain activity patterns. Its Evoke platform helps identify differences in neurological functions across various conditions. The company continues building partnerships that connect healthcare providers with new treatment options.The AIFF stock rally reflects market attention following the announcement of the healthcare collaboration. Firefly and NeuroSigma are combining their platforms to improve access to ADHD care solutions. The companies aim to support clinicians with assessment tools and alternative treatment pathways.Firefly Neuroscience operates in the precision neuroscience sector through its Evoke platform and research programs. The company focuses on using brain data to improve clinical decision-making processes. Meanwhile, NeuroSigma develops bioelectronic medical devices for neurological and psychiatric conditions.The partnership creates a wider channel for Monarch eTNS adoption among healthcare providers. Furthermore, it strengthens Firefly’s position in the growing digital neuroscience market. The companies will continue supporting clinician education and patient access through the collaboration. The post Firefly Neuroscience Inc. (AIFF) Stock: Surges 35% After NeuroSigma ADHD Therapy Partnership appeared first on Blockonomi.